MBIO stock falls 1.91 percent as Q2 loss widens

Published on 10/05/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MBIO stock traded at USD 0.46 on October 5, 2026, while Mustang Bio posted a Q2 loss of USD 1.1 million. Cash stood at USD 15.2 million.

MBIO, US62818Q3020, Illustration mit AI erstellt.

Mustang Bio stock (ISIN US62818Q3020) was trading at USD 0.46 on Nasdaq at 11:14 a.m. ET on October 5, 2026, down 1.91 percent from USD 0.47. The latest reported quarter showed a net loss of USD 1.1 million, widening from USD 762,000 a year earlier, according to TheDesperateTrader on August 5, 2026.

Q2 loss widens to USD 1.1 million

The second-quarter result covered the three months ended June 30, 2026. Diluted EPS was negative USD 0.16, compared with the continuing loss profile highlighted in the filing coverage by TheDesperateTrader.

Cash on hand stood at USD 15.2 million at June 30, 2026. The quarter also produced operating cash flow of negative USD 967,000, while the finance statement shows cash of USD 16.258 million at March 31, 2026, putting the quarterly cash balance USD 1.108 million lower.

Clinical pipeline carries the story

Mustang Bio describes itself as a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers. Its investor-relations page says the company acquires or licenses technologies, funds research and development, and seeks to outlicense or commercialize those programs, according to Mustang Bio.

The company highlights partnerships with medical institutions for CAR-T therapies. Its pipeline spans hematologic malignancies, autoimmune diseases and solid tumors, giving the stock a development-stage profile in which clinical progress and funding capacity are closely connected.

Stock sits 75.14 percent below high

At USD 0.46, MBIO stood 75.14 percent below its 52-week high of USD 1.85 and at the quoted 52-week low of USD 0.46. The market capitalization was USD 3.5 million, and trading volume reached 11,551 shares as of the October 5, 2026 intraday quote.

For investors, the current figures put the emphasis on cash use and upcoming clinical execution rather than revenue scale. Mustang Bio stock was last at USD 0.46 on Nasdaq on October 5, 2026 at 11:14 a.m. ET.